2008-2016

Gene Therapy Pioneers

Etapes de production d’un médicament de thérapie génique

Over the years, Genethon has proved capable of accompanying a candidate drug from the preclinical stages through to human clinical trials. Genethon applies its skills both to gene therapy projects that have been developed in its own laboratories and to those conducted by external teams.

Since 2005 Genethon has had its own manufacturing capacity for the production of gene therapy vectors according to the standards of Good Manufacturing Practices and In 2013, Genethon opened a new production center, Genethon BioProd, which is authorized to operate as a Pharmaceutical Establishment, to manufacture therapeutic candidates for clinical trials in France or abroad in strict compliance with regulations for pharmaceutical products.

On November 2, 2016, AFM-Téléthon and the SPI fund, managed by Bpifrance under the Programme d’Investissement d’Avenir, are creating YposKesi, the first French industrial pharmaceutical company dedicated to producing gene and cell therapy drugs for rare diseases

This new company aims to make the first treatments available to patients and market them at a fair and controlled price, consistent with the commitment made by AFM-Téléthon and its founders’ characteristic general interest strategy.

Genethon BioProd and its teams have integrated YposKesi. Ultimately, YposKesi will include three production buildings for gene and cell therapies.